JP2018048151A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018048151A5 JP2018048151A5 JP2017192907A JP2017192907A JP2018048151A5 JP 2018048151 A5 JP2018048151 A5 JP 2018048151A5 JP 2017192907 A JP2017192907 A JP 2017192907A JP 2017192907 A JP2017192907 A JP 2017192907A JP 2018048151 A5 JP2018048151 A5 JP 2018048151A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- cancer stem
- brain tumor
- pharmaceutical composition
- stem cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 210000000130 stem cell Anatomy 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 230000004663 cell proliferation Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 102000050554 Eph Family Receptors Human genes 0.000 claims 1
- 108091008815 Eph receptors Proteins 0.000 claims 1
- 102000051096 EphA2 Receptor Human genes 0.000 claims 1
- 108010055196 EphA2 Receptor Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 238000009792 diffusion process Methods 0.000 claims 1
- 108060002566 ephrin Proteins 0.000 claims 1
- 102000012803 ephrin Human genes 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10185930.4 | 2010-10-01 | ||
| EP10185930A EP2446895A1 (en) | 2010-10-01 | 2010-10-01 | EPH receptor expression in tumor stem cells |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015200808A Division JP6523910B2 (ja) | 2010-10-01 | 2015-10-09 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019205190A Division JP2020037579A (ja) | 2010-10-01 | 2019-11-13 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018048151A JP2018048151A (ja) | 2018-03-29 |
| JP2018048151A5 true JP2018048151A5 (enExample) | 2018-05-17 |
| JP6618968B2 JP6618968B2 (ja) | 2019-12-11 |
Family
ID=43856109
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013530753A Pending JP2013540117A (ja) | 2010-10-01 | 2011-09-30 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
| JP2015200808A Active JP6523910B2 (ja) | 2010-10-01 | 2015-10-09 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
| JP2017192907A Active JP6618968B2 (ja) | 2010-10-01 | 2017-10-02 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
| JP2019205190A Pending JP2020037579A (ja) | 2010-10-01 | 2019-11-13 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013530753A Pending JP2013540117A (ja) | 2010-10-01 | 2011-09-30 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
| JP2015200808A Active JP6523910B2 (ja) | 2010-10-01 | 2015-10-09 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019205190A Pending JP2020037579A (ja) | 2010-10-01 | 2019-11-13 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9078857B2 (enExample) |
| EP (2) | EP2446895A1 (enExample) |
| JP (4) | JP2013540117A (enExample) |
| KR (2) | KR101719966B1 (enExample) |
| AU (1) | AU2011310109B2 (enExample) |
| CA (1) | CA2813101C (enExample) |
| DK (1) | DK2621513T3 (enExample) |
| ES (1) | ES2616444T3 (enExample) |
| NZ (1) | NZ609594A (enExample) |
| PL (1) | PL2621513T3 (enExample) |
| WO (1) | WO2012042021A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20171143A1 (es) | 2010-12-08 | 2017-08-10 | Stem Centrx Inc | Nuevos moduladores y metodos para su uso |
| SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
| EP2733206A1 (en) * | 2012-11-19 | 2014-05-21 | Naroa LLC | Method for the isolation for mammalian stem cells using EphA2 and uses thereof |
| AR098221A1 (es) | 2013-11-04 | 2016-05-18 | Pfizer | Conjugados de anticuerpo anti-efna4-fármaco |
| WO2015168019A2 (en) | 2014-04-30 | 2015-11-05 | Pfizer Inc. | Anti-ptk7 antibody-drug conjugates |
| JP6921755B2 (ja) * | 2014-12-10 | 2021-08-18 | ハイパーステム ソシエテ アノニム | 脳腫瘍幹細胞の成長、遊走および浸潤性を低下させ脳腫瘍患者の生存率を改善する方法および組成物 |
| US10783439B2 (en) * | 2015-05-08 | 2020-09-22 | FlowJo, LLC | Plugin interface and framework for integrating a remote server with sample data analysis software |
| IL289849B2 (en) | 2015-11-10 | 2024-01-01 | Nat Inst Biotechnology Negev Ltd | Means and methods for reducing tumorigenicity of cancer stem cells |
| CN115379845B (zh) * | 2020-03-31 | 2024-10-25 | 学校法人庆应义塾 | 使用了基因组编辑多能干细胞的治疗药 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005037233A2 (en) * | 2003-10-15 | 2005-04-28 | Medimmune, Inc. | Listeria-based epha2 vaccines |
| US20060040325A1 (en) * | 2004-08-16 | 2006-02-23 | Medimmune, Inc. | Integrin antagonists with enhanced antibody dependent cell-mediated cytoxicity activity |
| US20070248628A1 (en) * | 2005-12-06 | 2007-10-25 | Keller Lorraine H | Immunogens in cancer stem cells |
| US8343461B2 (en) * | 2006-03-08 | 2013-01-01 | Wake Forest University Health Sciences | Molecular signature of cancer |
| LT2199390T (lt) * | 2007-08-30 | 2017-03-10 | Daiichi Sankyo Company, Limited | Anti-epha2 antikūnas |
-
2010
- 2010-10-01 EP EP10185930A patent/EP2446895A1/en not_active Withdrawn
-
2011
- 2011-04-18 US US13/089,217 patent/US9078857B2/en active Active
- 2011-09-30 PL PL11778540T patent/PL2621513T3/pl unknown
- 2011-09-30 DK DK11778540.2T patent/DK2621513T3/en active
- 2011-09-30 CA CA2813101A patent/CA2813101C/en active Active
- 2011-09-30 KR KR1020167002577A patent/KR101719966B1/ko active Active
- 2011-09-30 NZ NZ609594A patent/NZ609594A/en unknown
- 2011-09-30 JP JP2013530753A patent/JP2013540117A/ja active Pending
- 2011-09-30 AU AU2011310109A patent/AU2011310109B2/en active Active
- 2011-09-30 KR KR1020137011310A patent/KR20130095286A/ko not_active Ceased
- 2011-09-30 WO PCT/EP2011/067114 patent/WO2012042021A1/en not_active Ceased
- 2011-09-30 EP EP11778540.2A patent/EP2621513B1/en active Active
- 2011-09-30 ES ES11778540.2T patent/ES2616444T3/es active Active
-
2015
- 2015-10-09 JP JP2015200808A patent/JP6523910B2/ja active Active
-
2017
- 2017-10-02 JP JP2017192907A patent/JP6618968B2/ja active Active
-
2019
- 2019-11-13 JP JP2019205190A patent/JP2020037579A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018048151A5 (enExample) | ||
| JP5902138B2 (ja) | 癌治療と幹細胞調節のための方法 | |
| MX2024010140A (es) | Nuevos metodos. | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| AR060150A1 (es) | Heteropentaciclos activos como inhibidores de quinasas, y su uso para tratar trastornos de la proliferacion celular | |
| JP2015520753A5 (enExample) | ||
| CN111065639A (zh) | 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途 | |
| JP2019516754A5 (enExample) | ||
| JP2016501013A5 (enExample) | ||
| JP2007526248A5 (enExample) | ||
| WO2007055941A3 (en) | Histone deacetylase inhibitors with aryl-pyrazolyl motifs | |
| WO2016145234A3 (en) | Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same | |
| Ding et al. | Overexpression of miR-582-5p inhibits the apoptosis of neuronal cells after cerebral ischemic stroke through regulating PAR-1/Rho/Rho axis | |
| CY1118073T1 (el) | Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης | |
| RU2015140572A (ru) | Способы лечения колоректального рака | |
| JP2013511560A5 (enExample) | ||
| JP2018023397A5 (enExample) | ||
| CN110062628A (zh) | 一种瑞卡帕布口服缓控释药物组合物及其用途 | |
| WO2018175323A4 (en) | Gemcitabine derivatives for cancer therapy | |
| JP2013507954A5 (enExample) | ||
| Pullamsetti et al. | From cancer biology to new pulmonary arterial hypertension therapeutics: targeting cell growth and proliferation signaling hubs | |
| Wang et al. | Gene therapy for vein graft failure | |
| JP2017516832A5 (enExample) | ||
| WO2005028617A3 (en) | Antisense inhibition of laminin-8 expression to inhibit human gliomas | |
| Maik-Rachline et al. | RAF, MEK and ERK inhibitors as anti-cancer drugs: Intrinsic and acquired resistance as a major therapeutic challenge |